Formidable Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $228K | Sell |
1,639
-419
| -20% | -$55.2K | 0.04% | 359 |
|
|
2026
Q1 | $253K | Sell |
2,058
-54
| -3% | -$7.56K | 0.04% | 343 |
|
|
2025
Q4 | $234K | Sell |
2,112
-113
| -5% | -$13.7K | 0.03% | 360 |
|
|
2025
Q3 | $247K | Sell |
2,225
-69
| -3% | -$7.84K | 0.04% | 355 |
|
|
2025
Q2 | $257K | Hold |
2,294
| – | – | 0.04% | 330 |
|
|
2025
Q1 | $257K | Buy |
2,294
+2
| +0.1% | +$206 | 0.04% | 329 |
|
|
2024
Q4 | $212K | Buy |
+2,292
| New | +$206K | 0.03% | 349 |
|
|
2024
Q2 | – | Sell |
-1,794
| Closed | -$131K | – | 410 |
|
|
2024
Q1 | $131K | Buy |
+1,794
| New | +$138K | 0.02% | 353 |
|
|
2023
Q1 | – | Sell |
-2,780
| Closed | -$239K | – | 328 |
|
|
2022
Q4 | $239K | Sell |
2,780
-1,275
| -31% | -$101K | 0.05% | 255 |
|
|
2022
Q3 | $283K | Sell |
4,055
-40
| -1% | -$2.52K | 0.07% | 222 |
|
|
2022
Q2 | $253K | Sell |
4,095
-203
| -5% | -$12.6K | 0.06% | 247 |
|
|
2022
Q1 | $256K | Sell |
4,298
-633
| -13% | -$40.5K | 0.05% | 270 |
|
|
2021
Q4 | $357K | Buy |
4,931
+25
| +0.5% | +$1.72K | 0.07% | 232 |
|
|
2021
Q3 | $343K | Buy |
4,906
+1,674
| +52% | +$118K | 0.06% | 249 |
|
|
2021
Q2 | $222K | Sell |
3,232
-1,924
| -37% | -$128K | 0.05% | 276 |
|
|
2021
Q1 | $342K | Buy |
5,156
+113
| +2% | +$7.29K | 0.07% | 202 |
|
|
2020
Q4 | $300K | Buy |
5,043
+685
| +16% | +$41.3K | 0.07% | 210 |
|
|
2020
Q3 | $271K | Buy |
4,358
+277
| +7% | +$19.2K | 0.08% | 190 |
|
|
2020
Q2 | $313K | Sell |
4,081
-1,000
| -20% | -$76.6K | 0.09% | 176 |
|
|
2020
Q1 | $380K | Buy |
5,081
+1,585
| +45% | +$110K | 0.15% | 126 |
|
|
2019
Q4 | $219K | Buy |
+3,496
| New | +$228K | 0.07% | 196 |
|
|
2019
Q3 | – | Sell |
-3,551
| Closed | -$233K | – | 163 |
|
|
2019
Q2 | $233K | Buy |
+3,551
| New | +$234K | 0.08% | 177 |
|
|
2017
Q4 | – | Sell |
-4,352
| Closed | -$353K | – | 139 |
|
|
2017
Q3 | $353K | Buy |
4,352
+752
| +21% | +$57.5K | 0.15% | 138 |
|
|
2017
Q2 | $255K | Sell |
3,600
-555
| -13% | -$36.9K | 0.13% | 135 |
|
|
2017
Q1 | $279K | Sell |
4,155
-105
| -2% | -$7.38K | 0.12% | 153 |
|
|
2016
Q4 | $305K | Sell |
4,260
-350
| -8% | -$26K | 0.15% | 132 |
|
|
2016
Q3 | $365K | Buy |
4,610
+50
| +1% | +$4.06K | 0.18% | 121 |
|
|
2016
Q2 | $395K | Hold |
4,560
| – | – | 0.22% | 112 |
|
|
2016
Q1 | $466K | Sell |
4,560
-345
| -7% | -$31.1K | 0.33% | 78 |
|
|
2015
Q4 | $491K | Sell |
4,905
-490
| -9% | -$51K | 0.34% | 71 |
|
|
2015
Q3 | $529K | Hold |
5,395
| – | – | 0.35% | 65 |
|
|
2015
Q2 | $632K | Buy |
5,395
+300
| +6% | +$32.8K | 0.4% | 61 |
|
|
2015
Q1 | $538K | Buy |
+5,095
| New | +$517K | 0.35% | 64 |
|
|
2014
Q4 | – | Sell |
-5,095
| Closed | -$527K | – | 73 |
|
|
2014
Q3 | $560K | Sell |
5,095
-65
| -1% | -$6.37K | 0.37% | 63 |
|
|
2014
Q2 | $428K | Buy |
5,160
+30
| +0.6% | +$2.33K | 0.26% | 92 |
|
|
2014
Q1 | $380K | Buy |
+5,130
| New | +$402K | 0.27% | 83 |
|
Other funds holding GILD
ECSS
Formidable Asset Management's GILD Position: Q2 2026 in Review
Formidable Asset Management reduced its Gilead Sciences (GILD) stake by 20% in Q2 2026, selling an estimated $55.2K and leaving 1,639 shares worth $228K. The position accounts for 0.04% of the portfolio, ranked #359.
Formidable Asset Management first reported a position in GILD in Q1 2014 and has held it in 36 quarters since. The position peaked at $632K in Q2 2015. 956 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Formidable Asset Management held 1,639 shares of Gilead Sciences worth $228K as of Q2 2026.
- Formidable Asset Management sold 419 Gilead Sciences shares in Q2 2026, an estimated $55.2K.
- Gilead Sciences made up 0.04% of Formidable Asset Management's portfolio in Q2 2026, its #359 holding.
- Formidable Asset Management first reported a position in Gilead Sciences in Q1 2014 and has held it in 36 quarters since.
- Formidable Asset Management's Gilead Sciences position peaked at $632K in Q2 2015.
- 956 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Formidable Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.